Latest Insider Transactions at Opiant Pharmaceuticals, Inc. (OPNT)
This section provides a real-time view of insider transactions for Opiant Pharmaceuticals, Inc. (OPNT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of OPIANT PHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of OPIANT PHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2022
|
Gabrielle Alison Silver Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+7.89%
|
-
|
|
Jun 14
2022
|
Ann L. Mac Dougall Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+6.63%
|
-
|
|
Jun 14
2022
|
Masuoka K. Lorianne Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+33.33%
|
-
|
|
Jun 14
2022
|
Richard J Daly Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+20.41%
|
-
|
|
Jun 14
2022
|
Craig A Collard Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+3.46%
|
-
|
|
Jun 13
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
5,491
-16.72%
|
$60,401
$11.09 P/Share
|
|
Jun 13
2022
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
4,037
+6.98%
|
$40,370
$10.94 P/Share
|
|
Jun 10
2022
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
1,663
+3.23%
|
$18,293
$11.5 P/Share
|
|
Jun 09
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
7,896
-19.39%
|
$94,752
$12.25 P/Share
|
|
Jun 07
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
800
-1.93%
|
$9,600
$12.86 P/Share
|
|
Jun 06
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
7,688
-15.62%
|
$92,256
$12.94 P/Share
|
|
Jun 03
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
10,264
-17.26%
|
$133,432
$13.59 P/Share
|
|
Jun 02
2022
|
Brian Gorman |
SELL
Open market or private sale
|
Direct |
1,148
-3.42%
|
$14,924
$13.52 P/Share
|
|
Jun 02
2022
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
9,736
-14.07%
|
$126,568
$13.88 P/Share
|
|
May 16
2022
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
27,150
+36.07%
|
$352,950
$13.54 P/Share
|
|
May 16
2022
|
Gabrielle Alison Silver Director |
BUY
Open market or private purchase
|
Direct |
2,500
+10.49%
|
$32,500
$13.29 P/Share
|
|
May 13
2022
|
Ann L. Mac Dougall Director |
BUY
Open market or private purchase
|
Direct |
3,000
+10.28%
|
$30,000
$10.93 P/Share
|
|
May 13
2022
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
3,689
+14.96%
|
$36,890
$10.49 P/Share
|
|
Jan 27
2022
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,995
-2.48%
|
$51,870
$26.15 P/Share
|
|
Jan 27
2022
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,518
-6.33%
|
$39,468
$26.19 P/Share
|
|
Jan 10
2022
|
Roger Crystal Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,058
-1.3%
|
$31,740
$30.49 P/Share
|
|
Jan 10
2022
|
Phil Skolnick Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
385
-1.58%
|
$11,550
$30.49 P/Share
|
|
Jan 10
2022
|
David D O'Toole Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
432
-1.2%
|
$12,960
$30.6 P/Share
|
|
Jan 04
2022
|
Roger Crystal Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+32.91%
|
-
|
|
Jan 04
2022
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+29.27%
|
-
|
|
Jan 04
2022
|
Brian Gorman |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+26.32%
|
-
|
|
Jan 04
2022
|
Mark Jason Heath Ellison Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+37.93%
|
-
|
|
Jan 04
2022
|
David D O'Toole Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+24.99%
|
-
|
|
Jan 04
2022
|
Phil Skolnick Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+33.01%
|
-
|
|
Sep 22
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
735
-6.62%
|
$18,375
$25.02 P/Share
|
|
Sep 22
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,834
+14.17%
|
$18,340
$10.0 P/Share
|
|
Sep 21
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
831
-4.13%
|
$19,944
$24.1 P/Share
|
|
Sep 21
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+16.52%
|
$20,000
$10.0 P/Share
|
|
Sep 16
2021
|
Roger Crystal Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
100
+1.92%
|
$2,300
$23.44 P/Share
|
|
Sep 14
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
1,571
-6.18%
|
$29,849
$19.24 P/Share
|
|
Sep 14
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
3,025
+10.12%
|
$30,250
$10.0 P/Share
|
|
Sep 14
2021
|
David D O'Toole Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
200
+0.41%
|
$3,800
$19.09 P/Share
|
|
Sep 14
2021
|
Brian Gorman |
BUY
Open market or private purchase
|
Direct |
1,312
+2.87%
|
$24,928
$19.01 P/Share
|
|
Sep 13
2021
|
Craig A Collard Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,206
+3.43%
|
$21,708
$18.01 P/Share
|
|
Sep 13
2021
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
2,500
+13.46%
|
$45,000
$18.13 P/Share
|
|
Sep 10
2021
|
Craig A Collard Director |
BUY
Open market or private purchase
|
Direct |
9,577
+41.36%
|
$172,386
$18.18 P/Share
|
|
Sep 07
2021
|
Thomas T. Thomas Director |
SELL
Open market or private sale
|
Direct |
822
-11.0%
|
$14,796
$18.0 P/Share
|
|
Sep 07
2021
|
Thomas T. Thomas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,475
+16.48%
|
$14,750
$10.0 P/Share
|
|
Aug 31
2021
|
Matthew R. Ruth Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+10.53%
|
$34,000
$17.34 P/Share
|
|
Aug 25
2021
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
50,269
-25.87%
|
$703,766
$14.69 P/Share
|
|
Aug 25
2021
|
Michael Sinclair Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,269
+20.55%
|
$251,345
$5.0 P/Share
|
|
Aug 24
2021
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
34,607
-19.37%
|
$519,105
$15.71 P/Share
|
|
Aug 24
2021
|
Michael Sinclair Director |
BUY
Exercise of conversion of derivative security
|
Direct |
34,607
+16.23%
|
$173,035
$5.0 P/Share
|
|
Aug 23
2021
|
Michael Sinclair Director |
SELL
Open market or private sale
|
Direct |
65,124
-31.13%
|
$1,041,984
$16.5 P/Share
|
|
Aug 23
2021
|
Michael Sinclair Director |
BUY
Exercise of conversion of derivative security
|
Direct |
65,124
+23.74%
|
$325,620
$5.0 P/Share
|